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Parkinson’s disease (PD), deﬁned as a neurodegenerative disorder, is characterized by the loss of dopami-
nergic neurons in the substantia nigra in the midbrain. Loss-of-function mutations in the parkin gene are
a major cause of autosomal recessive, early-onset PD. Parkin has been implicated in the maintenance of
healthy mitochondria, although previous studies show conﬂicting ﬁndings regarding mitochondrial
abnormalities in ﬁbroblasts from patients harboring parkin-null mutations. The aim of the present study
was to determine whether South African PD patients with parkin mutations exhibit evidence for mito-
chondrial dysfunction. Fibroblasts were cultured from skin biopsies obtained from three patients with
homozygous parkin-null mutations, two heterozygous mutation carriers and two wild-type controls.
Muscle biopsies were obtained from two of the patients. The muscle ﬁbers showed subtle abnormalities
such as slightly swollen mitochondria in focal areas of the ﬁbers and some folding of the sarcolemma.
Although no differences in the degree of mitochondrial network branching were found in the ﬁbroblasts,
ultrastructural abnormalities were observed including the presence of electron-dense vacuoles. More-
over, decreased ATP levels which are consistent with mitochondrial dysfunction were observed in the
patients’ ﬁbroblasts compared to controls. Remarkably, these defects did not manifest in one patient,
which may be due to possible compensatory mechanisms. These results suggest that parkin-null patients
exhibit features of mitochondrial dysfunction. Involvement of mitochondria as a key role player in PD
pathogenesis will have important implications for the design of new and more effective therapies.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Parkinson’s disease (PD) is a common neurodegenerative disor-
der with global incidence rates of 1–2% in individuals over the age
of 65 and 4% over the age of 80 years [1]. Pathologically, PD is
deﬁned as the progressive loss of the dopaminergic neurons in
the substantia nigra pars compacta in the midbrain and clinicalmotor symptoms include bradykinesia, postural instability, rigidity
and resting tremor. Although PD has been associated with various
environmental factors, a number of genes have been found to
cause familial PD, with both autosomal dominant and autosomal
recessive patterns [2]. To date, the genes involved in autosomal
dominant forms of PD include SNCA, LRRK2, EIF4G1 and VPS35,
and those that are implicated in autosomal recessive PD, which
result in a loss-of-function, include parkin, PINK1, DJ-1 and ATP13A2
[3].
Parkin mutations are the predominant cause of autosomal
recessive PD, and are involved in the early-onset form of the disor-
der in which individuals typically under the age of 50 are affected
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of the ubiquitin–proteasome system (UPS) whereby cytosolic,
secretory and membrane proteins undergo degradation [5]. These
unwanted proteins are tagged for removal by the parkin protein,
which has also been involved in the removal of dysfunctional mito-
chondria from the cell via the process of mitophagy (selective deg-
radation of mitochondria). Absence of parkin is thought to lead to
the accumulation of critical substrates, resulting in the initiatory
events that induce changes in mitochondrial structure and func-
tion [6].
Animal knockout models of parkin show several changes in the
mitochondria in comparison to the wild-type controls. A study on a
Drosophila knockout model revealed that mitochondrial defects
were a common characteristic of the pathology [7]. Severe mor-
phological features were observed, including irregular and dis-
persed myoﬁbrillar arrangements and swollen and malformed
mitochondria with disintegration of cristae. In mice knockout
models, a decrease in the number of proteins involved in mito-
chondrial function and oxidative stress, lowered respiratory capac-
ity of striated muscle mitochondria, as well as decreased serum
antioxidant capacity were observed [8]. Human studies performed
on leukocytes, ﬁbroblasts and post mortem brain tissue obtained
from PD patients with parkin-null mutations have further impli-
cated structural and functional mitochondrial impairment [9–13].
In particular, human ﬁbroblasts have been used as a primary cell
model of PD [14], as expression levels of parkin are at relevant
quantities in these cells.
Studies on ﬁbroblasts have noted ultrastructural changes in the
mitochondria such as larger mitochondrial mass [9] as well as
grossly swollen mitochondria with disintegrated cristae [12]. How-
ever, studies on the mitochondrial network in ﬁbroblasts have
been controversial. Findings include no differences in the network
of patient ﬁbroblasts compared to controls [9], or an increase in
mitochondrial branching in patient cells, indicating a possible
increase in fusion [11]. Other studies have observed a fragmented
mitochondrial network, suggesting that impaired mitochondrial
fusion is present in parkin-null mutants [12].
Functional studies on the respiratory capacity of the mitochon-
drial electron transport chain complexes have shown a signiﬁcant
decrease in the activity of complex I in both ﬁbroblasts and leuko-
cytes from patients with parkin mutations in comparison to age-
matched controls [15]. Impaired mitochondrial respiration usually
results in ATP depletion which causes increased levels of reactive
oxygen species (ROS), and eventually cell death. Studies on ﬁbro-
blasts from parkin-null patients have shown varying results
regarding the levels of ATP, with some showing signiﬁcant reduc-
tion [9,11] and others showing a signiﬁcant increase in ATP levels
[12].
It is clear that further studies on ﬁbroblasts harboring parkin-
null mutations are needed, as previous studies have produced con-
ﬂicting ﬁndings. In the present study, mitochondrial functional and
structural analysis was performed on ﬁbroblasts from three PD
patients, all with parkin-null mutations. Muscle biopsies were
assessed for mitochondrial defects. Furthermore, two heterozygous
carriers of the parkin-null mutations were included for comparison
with the homozygous patients.2. Materials and methods
2.1. Ethics statement
The study protocol was approved by the Health Research Ethics
Committee at Stellenbosch University, South Africa (Protocol num-
ber 2002/C059) and all study participants provided informed writ-
ten consent.2.2. Study participants
For the present study, three PD patients, each with two parkin
null mutations were selected, one sporadic patient with Mixed
Ancestry ethnicity (P1) and two White Afrikaner siblings (P2 and
P3). The patients were examined by a movement disorder special-
ist (JC), and all met the UK Parkinson’s Disease Society Brain Bank
Research criteria for diagnosis of PD [16]. The exonic deletion
mutations had been identiﬁed in these patients in previous studies
using multiplex ligation-dependent probe ampliﬁcation (MLPA)
and cDNA sequencing; P1 has homozygous deletions of exons 3
and 4, whereas P2 and P3 have homozygous deletions of exon 4
[17–19]. Also included in the study were unaffected family mem-
bers of the patients who are heterozygous carriers of the muta-
tions. These included P1het (the mother of patient P1) and P2het
(the sibling of sisters P2 and P3). In addition, two wild-type con-
trols, WTC1 and WTC2, were included who did not harbor muta-
tions in parkin and had no history of neurological disease.
Phenotypic and genotypic data of the PD patients, heterozygous
carriers and controls are summarized in Supplementary Table 1.
2.3. Fibroblast culture from skin biopsies
Fibroblasts were obtained from all three PD patients, both car-
riers and both WT controls, from a skin punch biopsy taken from
the inner upper arm. The 2 mm  2 mm skin piece was suspended
in a solution of Dulbecco’s Modiﬁed Eagle’s Medium (DMEM; Lon-
za, Switzerland) with 10% fetal calf serum and 1% penicillin
(1000 U/ml) streptomycin (1000 U/ml). The cells were grown in
25 cm2 culture ﬂasks at 37 C, 5% CO2. For all experiments the pas-
sage number was kept to below 12.
2.4. Muscle biopsies
Muscle biopsies were obtained from patients P1 and P2 but not
from P3 as she exhibited severe tardive dyskinesias on the day of
the procedure. Muscle biopsies were not requested from the WT
controls or the carriers. For the biopsies an area of skin overlying
the vastus lateralis muscle was sterilely prepared with 5% povi-
done iodine and 0.5% chlorhexidine. Thereafter, 2% lignocaine
hydrochloride local anesthetic was injected intra- and subcutane-
ously in a 4 cm2 area. A 1 cm longitudinal incision was made
through the skin and fascia, and three percutaneous muscle biop-
sies were extracted using a 5 mm Bergström biopsy needle. A piece
of muscle tissue was dissected with a scalpel and immediately
ﬁxed in gluteraldehyde buffer for electron microscopy studies.
The remainder of the muscle tissue was snap frozen and stored
in liquid nitrogen until sectioning.
2.5. Live cell imaging and analysis of mitochondrial morphology
Mitochondrial morphology was assessed by ﬂuorescence
microscopy. Human ﬁbroblasts were seeded in Lab-Tek 8-well cov-
erglasses (Nunc, 155411, Thermo Scientiﬁc). Mitochondria were
stained with 200 nM Mitotracker Red (Invitrogen, Life Technolo-
gies, USA) and nuclei counterstained with Hoechst 33342 (Invitro-
gen, Life Technologies, USA). Image acquisition was performed on
an Olympus IX-81 microscope coupled to an MT-20 Xenon-arc bur-
ner (Olympus Biosystems GMBH) and equipped with a F-view-II
cooled CCD camera (Soft Imaging systems) and an environmental
chamber (Solent Scientiﬁc). Images were acquired using 360 nm
and 572 nm excitation and a UBG triple bandpass emission ﬁlter
cube (Chroma). Z-stacking was performed with an increment of
0.26–0.3 lm between image frames, using an Olympus Plan Apo
N60x/1.4 oil immersion objective. A total of 7–12 image frames
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exported as TIFF ﬁles for further processing and analysis.
The live cell imaging experiments were done in triplicate (n = 3)
and a total of ten images were taken per sample for each experi-
mental run. Clearly visible cells were individually analyzed using
Image J 1.41o software giving a total average of 80 cells analyzed
per sample across all experimental runs. All images were opti-
mized by contrast adjustment and binarized by conversion to 8
bit image types. Unspeciﬁc noise of the ﬂuorescent signal was
reduced and a threshold applied to the images. Using Image J, mor-
phological characteristics of each mitochondrion per cell were ana-
lyzed, including area, perimeter, as well as major and minor axes.
These individual parameters were used to calculate mitochondrial
mass, the aspect ratio (ratio between the major and minor axes of
the ellipse equivalent to the object), and its form factor (perime-
ter2/(4p  area)), which is consistent with the degree of branching.
2.6. Structural and ultrastructural analysis of the muscle biopsies and
the ﬁbroblasts
Transmission electron microscopy (TEM) was performed on
both the muscle ﬁbers and the ﬁbroblasts to identify ultrastruc-
tural changes in the cells and mitochondria of patients and carriers
in comparison to the wild type controls. Muscle biopsies were ori-
entated and frozen in n-pentane, which was cooled in liquid nitro-
gen. 10–20 lm cryostat sections were cut. In addition to the
section stained with hematoxylin and eosin, the following histo-
chemical stains were performed routinely at 37 C in a humidity
chamber: Adenosine Triphosphatase (ATPase); Nicotinamide Ade-
nine Dehydrogenase (NADH); Succinate Dehydrogenase (SDH).
Furthermore, Periodic Acid Schiffs (PAS); Oil red O and Gomori Tri-
chrome stains were performed. The sections for light microscopy
were viewed using the Olympus BX41 microscope (Olympus,
Germany).
The portion for electron microscopy was post-ﬁxed in 1%
osmium tetroxide, stained en-bloc with uranyl acetate and then
dehydrated through graded alcohols and embedded in Epoxy resin.
One micrometer thick sections were stained with 1% toluidine blue
in 5% Borax. Six ultrathin sections were mounted on copper grids
and stained with a saturated solution of uranyl acetate, followed
by lead citrate for 6 min each. Ultrastructural investigation was
performed using a Zeiss EM109 transmission electron microscope
(Oberkochen, Germany).
The ﬁbroblast cells were processed with a Leica automatic tis-
sue processor. Sections were cut with glass knives, using Leica
ultra-microtome, and placed on 200 mesh copper grids. The grids
were scoped with a JEOL 10-11 transmission microscope (JEOL,
Japan) and a SIS imaging system was used to view the cells.
2.7. Assessment of intracellular ATP levels
ATP levels were determined using the Enliten ATP Biolumines-
cence Detection kit (Promega, USA). The assay uses recombinant
luciferase to catalyze the following reaction:
ATPþ D-Luciferinþ O2 ! Oxyluciferinþ AMPþ PPiþ CO2 þ Light
The intensity of the emitted light is proportional to the ATP
concentration.
Fibroblasts were seeded in 25 cm2 ﬂasks at a count of 100,000
cells per individual and incubated at 37 C, 5% CO2 until they
reached 80% conﬂuence. Following this, the ﬁbroblasts were tryp-
sinized and collected by centrifugation at 1000 rpm and washed
with PBS. The cell pellets were resuspended in 50 ll ice cold
extraction buffer (100 mM Tris–HCl and 4 mM EDTA, pH 7.75).
Immediately thereafter, 150 ll boiling extraction buffer was addedand samples were incubated at 99 C for 2 min. Thereafter, the
samples were centrifuged at 10 000 rpm for 1 min and superna-
tants were collected. Measurement of ATP levels was performed
in three separate experiments (n = 3), each in duplicate on a lumi-
nometer, using 50 ll sample and 50 ll of luciferase reagent.2.8. Statistical analysis
Linear mixed-effects models of the various outcomes mitochon-
drial mass, aspect ratio, form factor and ATP levels, were used with
predictors individuals and groups (patients, heterozygote carriers
and WT controls), respectively, as ﬁxed effects. Experiments, indi-
viduals (when comparing groups) and an indicator of relatedness
were used as random effects, to adjust the correlation between
individuals and between experiments inside individuals and for
relatedness (grouping of family members). The values for both
mitochondrial mass and ATP levels and were log transformed to
approximate normality prior to analysis. The freely available pro-
gram R (www.r-project.org) and function lme from the R package
nlme was used for the analysis [20]. p values of <0.05 were
regarded as statistically signiﬁcant.3. Results
3.1. Mitochondrial network was unaffected
Given that the functional state of mitochondria is often
reﬂected in their morphology, we investigated various morpholog-
ical parameters such as form factor, aspect ratio and mitochondrial
mass in all patients and carriers compared to control cells. For all
parameters no differences were observed either at an individual
level or as groups (p > 0.05 for all) (Fig. 1A and B).3.2. Ultrastructural alterations observed
TEM was used for more detailed ultrastructural analysis of the
mitochondrial morphology. The ﬁbroblasts of the control
(Fig. 2A) showed rod-like shaped mitochondria, with intact cristae
and membranes. Vacuoles present in the control cells were pre-
dominantly clear. By comparison, electron-dense (darker) vacuoles
thought to be lysosomes were observed in all three patients, but to
a lesser degree in P3 (Fig. 2B–D). In addition, mostly spherical
mitochondria were observed in patient P1’s ﬁbroblasts (Fig. 2B).
Fig. 2E indicates a mitochondrion possibly in the process of being
engulfed by autophagosomal or lysosomal structures, and thus it
could be speculated that the electron dense material is degraded
mitochondria. No ultrastructural alterations were evident in the
heterozygous carriers (data not shown).3.3. Decreased ATP levels
Two of the patients exhibited statistically signiﬁcant lower ATP
levels compared to an average of the controls. Patients P1 and P2
showed a 41.8% (p = 0.0091) and 36.3% (p = 0.0195) decrease,
respectively (Fig. 3). Patient P3 showed only a 9.3% decrease, which
was not statistically signiﬁcant (p = 0.5022). Although both carriers
showed no statistically signiﬁcant difference in ATP levels, P2het
exhibited a 29.4% decrease (p = 0.0893).
In addition, the three groups i.e. patients, carriers and controls
were simultaneously compared, yielding a combined p-value of
0.0191. Investigating pairwise differences, the combined patients
differed highly signiﬁcantly from the controls (29% decrease,
p = 0.0058), whereas the carriers did not differ signiﬁcantly from
the controls (15% decrease, p = 0.1584).
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Fig. 1. Morphology of the mitochondrial network in ﬁbroblasts. (A) Representative images of control and parkin-mutant ﬁbroblasts. Mitotracker Red was used to visualize the
mitochondrial network and the nuclei were counterstained with Hoechst 33342. Scale bar: 20 lm. (B) Boxplots showing the distributions of aspect ratio, form factor and
mitochondrial mass, and analysis of the data revealed that there were no differences in mitochondrial branching between the patient, carrier and control groups (p > 0.05).
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No signiﬁcant abnormalities were found on light microscopic
examination of the muscle biopsy of P1 whereas for P2 a milddegree of muscle ﬁber atrophy was found, which was regarded
as non-signiﬁcant and probably age related. Except for focal accu-
mulations of slightly swollen mitochondria, no mitochondrial
abnormalities were detected on TEM of either muscle biopsy
A WTC1 B P1
C P1 P2D
E P3
Fig. 2. Transmission electron microscopy images of ﬁbroblasts. (A) Fibroblasts of the control indicating rod-like shaped mitochondria (asterix), and clear vacuoles (arrow). (B)
Spherical mitochondria (asterix) and (C) dark, electron-dense vacuoles (arrow) were observed in patient P1 and (D) P2’s cells. (E) In patient P3’s ﬁbroblasts the presence of a
mitochondrion (asterix) close to a vacuole (arrow) is observed, which may be an indication that the mitochondrion is in the process of being engulfed. Scale bar: A and C,
1 lm; B and D, 2 lm; E, 0.5 lm.
Fig. 3. Boxplots showing distributions of ATP levels. ATP levels were measured in arbitrary units of ATP luminescence and signiﬁcant differences were found between the
patient and control groups.
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biopsies, a non-speciﬁc ﬁnding possibly related to mild atrophy.
Additionally, accumulations of intermyoﬁbrillar glycogen was vis-
ible on TEM of P2, the signiﬁcance of which is uncertain.4. Discussion
In the present study, we investigated the effect of parkin-null
mutations on the structure and function of mitochondria in ﬁbro-
Fig. 4. Transmission electron microscopy images of muscle ﬁbers. (A and B)
Patients P1 and (C and D) P2. Normal appearing mitochondria (solid, thin arrows)
and slightly swollen mitochondria (dashed arrows) can be seen in the muscle of
both patients (images A and C). Folding of the sarcolemma, probably indicative of
mild atrophy can also be seen in both biopsies (open arrows; images B and D).
Additionally, small collections of intermyoﬁbrillar glycogen can be seen in the
images from P2 (short arrows, images C and D).
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ences were observed in the mitochondrial network, subtle mor-
phological alterations and decreased ATP levels were found in
two of the three patients compared to the controls. No defects
were observed in the heterozygous mutation carriers. In muscle
biopsies obtained from two of the patients subtle abnormalities
were detected.
Structural analysis of the mitochondrion allows identiﬁcation of
defects which could impair mitochondrial function, and that could
ultimately affect the overall cellular function. Tubular networks are
formed through the processes of fusion and ﬁssion, and provide an
indication of the maintenance of mitochondrial function. In the
present study we found no differences in the mitochondrial net-
work morphology between the patients and the controls. This con-
curs with a previous study on parkin-mutant ﬁbroblasts that also
showed no differences under basal culturing conditions [9]. It has
been speculated that parkin- and PINK1-deﬁcient cells may require
additional stressors (rotenone, paraquat, oxidative stress, etc.) to
induce a mitochondrial fragmentation phenotype [9,21,22].
Ultrastructural analysis of the patients’ ﬁbroblasts revealed a
mixture of rod-shaped and circular mitochondria that appeared
swollen, as well as electron dense autophagic vacuoles, which
has been observed previously [12]. Cellular vacuoles house hydro-
lytic enzymes (lysosomes), and function as exporters of waste in
the cell. The cellular material observed within these vacuoles
may be accumulated proteins or damaged mitochondria whichare aggregating due to the absence of parkin, thus resulting in
autophagosomes. However, further work is needed to determine
the nature of the material inside these vacuoles before any conclu-
sions can be drawn.
In addition, signiﬁcantly decreased ATP levels were detected in
two of the three patients. This corresponds with the hypothesis
that ATP generation in these ﬁbroblasts is predominantly via the
less efﬁcient glycolysis pathway. Previous studies have conﬂicted
with regards to ATP levels, although some of these seem to agree
that ATP levels are decreased in patient ﬁbroblasts with parkin
mutations [9,11].
The signiﬁcance of the muscle ﬁber atrophy observed on TEM of
both patients is uncertain, as it was very mild and is a non-speciﬁc
ﬁnding. In the case of P2, where it was also seen on light micros-
copy, this ﬁnding can probably be explained by sarcopenia (the
loss of skeletal muscle mass and strength as a result of aging) as
P2 is 13 years older than P1. Although it would be expected that
more severe mitochondrial alterations would be reﬂected in the
more energy-demanding muscle tissue, the changes detected in
the ﬁbroblasts were not observed in the muscle ﬁbers. The reasons
for this discrepancy are not known but generally, post-mitotic tis-
sue with high metabolic energy requirements, such as muscle, is
preferentially affected in mitochondrial disorders. However, these
disorders, caused by either mitochondrial or DNA mutations,
directly affect energy production. Whether the same holds true
for mutations that are implicated in altered mitophagy or ubiquiti-
nation of substrate proteins, as seen in parkin mutations, is
unknown. Of note, mutations in MFN2, which encodes the mito-
chondrial-fusion promoting factor mitofusin 2, and cause an inher-
ited neuropathy are not known to affect muscle tissue [23]. To our
knowledge there has only been one other published report on mus-
cle morphology in a parkin-mutant patient [24]. This study found
features of mitochondrial muscle pathology in a single patient
but whether the two conditions, PD and mitochondrial myopathy
were unrelated and occurred co-incidentally in this patient is not
clear. The pattern of mitochondrial involvement in PD and related
disorders therefore remains to be investigated.
A limitation of the present study was the limited number of
samples and therefore follow-up studies will include larger num-
bers of patients and controls. Future studies will also focus on mea-
suring ATP synthesis rates, the activity of individual mitochondrial
complexes, ROS levels and the mitochondrial membrane potential.
Moreover, although ﬁbroblasts have been shown to be a good cell
model to study disease mechanisms in PD [14], it would be of
interest to determine whether the defects that we have observed,
and other features of oxidative stress [25], are also present in neu-
ral cells generated from induced pluripotent stem cells (iPSCs) of
these and other PD patients.
In conclusion, our results on South African patients concur with
previous studies that mitochondrial dysfunction is present in PD
patients with parkin null mutations. Subtle alterations were found
in the mitochondria of the ﬁbroblasts at both a morphological and
functional level. Interestingly, one of the three patients (P3) did not
show these defects. The reasons for this are currently unknown
although the patient is known to have had a less severe phenotype
and a slower disease progression in comparison to her sibling (P2).
These preliminary ﬁndings indicate that there may be compensa-
tory biological mechanisms such as differences in autophagic
activity which could result in different phenotypes being observed
between individuals when using patient-derived cells. These com-
pensatory mechanisms may in part explain the variable and con-
ﬂicting results reported to date. Further work is necessary in
iPSC-derived neurons from larger numbers of patients harboring
PD-causing mutations and controls in order to determine if the
observed differences found in ﬁbroblasts are mirrored in neuronal
cells.
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